RegulatoryEconomic Times
US drug regulator classifies Aurobindo Pharma arm's Andhra facility as 'voluntary action indicated'
Neutral0
GreyOak summary
Aurobindo Pharma's subsidiary, Apitoria Pharma, received a Voluntary Action Indicated (VAI) classification from the USFDA for its API manufacturing unit in Andhra Pradesh. The inspection, conducted between August 24-28, 2026, resulted in three observations but no recommended administrative action. The USFDA has officially closed the inspection.
What it affects
- Aurobindo PharmaAUROPHARMANeutral 0
USFDA inspection closed with VAI classification.Rolling sentiment Negative -19
Source
Reported by Economic Times
More Aurobindo Pharma news
- Aurobindo Pharma's Apitoria unit gets 'voluntary action indicated' classification from USFDACNBC-TV18 · Regulatory ·
- Geojit raises Aurobindo Pharma target to Rs 2111Moneycontrol · Company update ·